Morning Side

Morningside Ventures is the venture capital investing arm of the Morningside Group, a long-standing private-capital platform founded in 1986 by Hong Kong-American brothers Gerald L. Chan, who serves as Chairman of Morningside Ventures, and Ronnie C. Chan, Chairman of Hang Lung Group. Headquartered in Newton, Massachusetts with additional operations in Hong Kong, the firm deploys patient capital across North America, Asia, and Europe with a long-term orientation and an explicit commitment to ethical practice. Life sciences is the dominant concentration, with the team recognized as a pioneer in oncolytic viral therapy, mitochondrial medicine, and innate-immunity modalities spanning toll-like receptors, the STING pathway, the complement cascade, and immune proteasomes. Portfolio companies have received seven FDA Breakthrough Therapy designations and twelve Fast Track designations — a track record few venture firms in any segment can match. The platform has made roughly 431 disclosed investments in aggregate. Average check sizes by stage are approximately $4.5 million at seed (17 deals), $23.9 million at Series A (42 deals), and $49.2 million at Series B (36 deals). Morningside leads rounds. Recent deals include leading a $105 million round in Cognito Therapeutics in March 2026, a $12 million Series B Plus in Accropeutics in March 2025, an $8.5 million pre-Series A in Ampa in October 2025, and an investment in digital health company Xealth in March 2025. The 2025 calendar saw 10 investments in total. Beyond capital, Morningside's philanthropic commitments to the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design reflect the firm's conviction that deep institutional relationships with leading research universities are essential to discovering and backing the next generation of breakthrough science.